Home > Insider Trading > Filing (0001209191-18-050736)

Filing Details

Accession Number:: 0001209191-18-050736
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2018-09-12 21:00:19
Reporting Period:: 2018-09-10

Accepted Time:: 2018-09-12 21:00:19
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1600132	Bellerophon Therapeutics Inc.	BLPH	()	4

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1277994	P L Iv Fund Entrepreneurs Venrock	C/O Venrock 3340 Hillview Avenue Palo Alto CA 94304	No	No	Yes	No
1277997	P L Iv Associates Venrock	C/O Venrock 3340 Hillview Avenue Palo Alto CA 94304	No	No	Yes	No
1305238	Venrock Management Iv, Llc	C/O Venrock 3340 Hillview Avenue Palo Alto CA 94304	No	No	Yes	No
1305239	Venrock Partners, L.p.	C/O Venrock 3340 Hillview Avenue Palo Alto CA 94304	No	No	Yes	No
1305240	Venrock Partners Management, Llc	C/O Venrock 3340 Hillview Avenue Palo Alto CA 94304	No	No	Yes	No
1305243	Vef Management Iv, Llc	C/O Venrock 3340 Hillview Avenue Palo Alto CA 94304	No	No	Yes	No
1602263	Vhcp Management Ii, Llc	C/O Venrock 3340 Hillview Avenue Palo Alto CA 94304	No	No	Yes	No
1602264	Venrock Healthcare Capital Partners Ii, L.p.	C/O Venrock 3340 Hillview Avenue Palo Alto CA 94304	No	No	Yes	No
1615979	Y Bong Koh	C/O Venrock 3340 Hillview Avenue Palo Alto CA 94304	No	No	Yes	No
1615983	Vhcp Co-Investment Holdings Ii, Llc	C/O Venrock 3340 Hillview Avenue Palo Alto CA 94304	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2018-09-10	200,000	$1.22	6,901,163	No	4	P	Indirect	By funds
Common Stock	Acquisiton	2018-09-11	200,000	$1.14	7,101,163	No	4	P	Indirect	By funds
Common Stock	Acquisiton	2018-09-12	75,000	$1.15	7,176,163	No	4	P	Indirect	By funds

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	By funds
No	4	P	Indirect	By funds
No	4	P	Indirect	By funds

Footnotes

This Form 4 is the first of two Form 4s being filed to report the beneficial ownership of the following Reporting Persons: Venrock Associates IV, LP, Venrock Partners, LP, Venrock Entrepreneurs Fund IV, LP, Venrock Management IV, LLC, Venrock Partners Management, LLC, VEF Management IV, LLC, Venrock Healthcare Capital Partners II, LP, VHCP Management II, LLC, VHCP Co Investment Holdings II, LLC, Venrock Healthcare Capital Partners III, LP, VHCP Management III, LLC, VHCP Co Investment Holdings III, LLC, Bong Koh and Nimish Shah. Two Form 4s are being filed because each form can report a maximum of 10 reporting persons.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.2099 to $1.2265, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
Consists of (i) 181,820 shares purchased by Venrock Healthcare Capital Partners III, LP and (ii) 18,180 shares purchased by VHCP Co-Investment Holdings III, LLC.
Venrock Management IV, LLC ("VM4") is the general partner of Venrock Associates IV, LP. Venrock Partners Management, LLC ("VPM") is the general partner of Venrock Partners, LP. VEF Management IV, LLC ("VEFM") is the general partner of Venrock Entrepreneurs Fund IV, LP. VHCP Management II, LLC ("VHCPM2") is the general partner of Venrock Healthcare Capital Partners II, LP and the manager of VHCP Co-Investment Holdings II, LLC. VHCP Management III, LLC ("VHCPM3") is the general partner of Venrock Healthcare Capital Partners III, LP and the manager of VHCP Co-Investment Holdings III, LLC. Bong Koh and Nimish Shah are the managing members of VHCPM2 and VHCPM3. Each of VM4, VPM, VEFM, VHCPM2, VHCPM3, Bong Koh and Nimish Shah (together, the "Managers") may be deemed to beneficially own these shares. Each of the Managers expressly disclaims beneficial ownership over these shares except to the extent of their indirect pecuniary interests therein.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.10894 to $1.1990, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
Consists of (i) 68,183 shares purchased by Venrock Healthcare Capital Partners III, LP and (ii) 6,817 shares purchased by VHCP Co-Investment Holdings III, LLC.